Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | IL1B | P01584 | 3/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326688 | 0.97 | NLRP3 (0.48) | NLRP3MEN1KMT2ATSHRKDM4E | |
| SCHEMBL29155893 | 0.87 | NLRP3 (0.47) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29975535 | 0.87 | NLRP3 (0.47) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29975213 | 0.87 | NLRP3 (0.47) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29326670 | 0.85 | NLRP3 (0.54) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29030601 | 0.83 | TNK2 (0.41) | MEN1KMT2ATSHRKDM4EHPGD | |
| SCHEMBL30488545 | 0.83 | TNK2 (0.41) | MEN1KMT2ATSHRKDM4EHPGD | |
| SCHEMBL25862365 | 0.83 | TNK2 (0.41) | MEN1KMT2ATSHRKDM4EHPGD | |
| SCHEMBL30488495 | 0.83 | TNK2 (0.41) | MEN1KMT2ATSHRKDM4EHPGD | |
| SCHEMBL25856345 | 0.83 | TNK2 (0.41) | MEN1KMT2ATSHRKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | NLRP3 1/4885MEN1 4346/4885KMT2A 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.